• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lung Cancer - Pipeline Review, H2 2012 Product Image

Lung Cancer - Pipeline Review, H2 2012

  • Published: October 2012
  • 687 pages
  • Global Markets Direct

Lung Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Cancer.
- A review of the Lung Cancer products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 16
List of Figures 26
Introduction 27
REPORT COVERAGE 27
Lung Cancer Overview 28
Therapeutics Development 29
An Overview of Pipeline Products for Lung Cancer 29
Lung Cancer Therapeutics under Development by Companies 31
Lung Cancer Therapeutics under Investigation by Universities/Institutes 49
Late Stage Products 73
Comparative Analysis 73
Mid Clinical Stage Products 74
Comparative Analysis 74
Early Clinical Stage Products 75
Comparative Analysis 75
Discovery and Pre-Clinical Stage Products 76
Comparative Analysis 76
Lung Cancer Therapeutics – Products under Development by Companies 77
Lung Cancer Therapeutics – Products under Investigation by Universities/Institutes 109
Companies Involved in Lung Cancer Therapeutics Development 176
Bristol-Myers Squibb Company 176
Johnson & Johnson 177
Boehringer Ingelheim GmbH 178
F. Hoffmann-La Roche Ltd. 179
Kyowa Hakko Kirin Co., Ltd. 180
Celsion Corporation 181
Abbott Laboratories 182
Biogen Idec Inc. 183
Helix BioPharma Corp. 184
Amgen Inc. 185
Sanofi-Aventis 186
AstraZeneca PLC 187
Eli Lilly and Company 188
Viralytics Ltd. 190
GlaxoSmithKline plc 191
Genentech, Inc. 192
Antigenics, Inc. 193
Bavarian Nordic A/S 194
MedImmune LLC 195
Isis Pharmaceuticals, Inc. 196
Daiichi Sankyo Company, Ltd 197
Merck & Co., Inc. 198
AbGenomics International, Inc. 199
FASgen, Inc. 200
A&G Pharmaceutical, Inc. 201
Infinity Pharmaceuticals, Inc. 202
Takeda Pharmaceutical Company Limited 203
YM BioSciences Inc. 204
Light Sciences Oncology, Inc. 205
Amorfix Life Sciences Ltd. 206
Ipsen S.A. 207
Celltrion, Inc. 208
ZIOPHARM Oncology, Inc. 209
Millennium Pharmaceuticals, Inc. 210
Novartis AG 211
Astellas Pharma Inc. 212
Biocon Limited 213
Cephalon, Inc. 214
Chong Kun Dang Pharmaceutical 215
Chugai Pharmaceutical Co. Ltd 216
Daewoong Pharmaceutical Co., Ltd. 217
Eisai Co., Ltd. 218
Human Genome Sciences, Inc. 219
MDRNA, Inc. 220
OSI Pharmaceuticals, Inc. 221
Pfizer Inc. 222
Taiho Pharmaceutical Co., Ltd. 223
Teva Pharmaceutical Industries Limited 224
Yakult Honsha Co., Ltd. 225
Cell Therapeutics, Inc. 226
Peregrine Pharmaceuticals, Inc. 261
Critical Outcome Technologies Inc. 262
Curis, Inc. 263
ARQULE, INC 264
ADVENTRX Pharmaceuticals 265
Allos Therapeutics, Inc 266
BTG International Ltd 267
Telik, Inc. 268
TopoTarget A/S 269
CytRx Corporation 270
Regeneron Pharmaceuticals, Inc. 271
Oncogenex Pharmaceuticals, Inc. 272
Dendreon Corporation 273
ProMetic Life Sciences Inc. 274
Transgene SA 275
MOLOGEN AG 276
Innocell Corporation 277
Quest PharmaTech Inc. 278
Jiangsu Hengrui Medicine Co., Ltd. 279
Threshold Pharmaceuticals, Inc. 280
Synta Pharmaceuticals Corp. 281
Natco Pharma Limited 282
Sareum Holdings plc 283
Simcere Pharmaceutical Group 284
Sun Pharma Advanced Research Company 285
Rexahn Pharmaceuticals, Inc. 286
Scancell Holdings Plc 287
Gunma University 288
Morphotek, Inc. 289
Oryzon 290
Debiopharm Group 291
Avanti Therapeutics 292
Chipscreen Biosciences Ltd 293
CIMAB S.A. 294
Supratek Pharma Inc. 295
Bionucleon Srl 296
Immupharma Plc 297
GANYMED Pharmaceuticals AG 298
Ora Bio Ltd. 299
Philogen S.p.A. 300
NovaRx Corporation 301
Actis Biologics, Inc 302
Med Discovery SA 303
CanBas Co., Ltd. 325
Merrimack Pharmaceuticals, Inc. 326
Neotropix, Inc. 327
ProNAi Therapeutics, Inc. 328
Mersana Therapeutics, Inc. 329
Jennerex Biotherapeutics, Inc. 330
Axelar AB 331
Proacta, Inc. 332
Omnitura Therapeutics Inc. 333
Advenchen Laboratories, LLC 334
MolMed S.p.A. 335
Pharminox Limited 336
Innogene Kalbiotech Pte Ltd. 337
Syndax Pharmaceuticals, Inc. 338
KangLaiTe USA 339
Mirna Therapeutics, Inc. 340
Transtech Pharma, Inc. 341
Welichem Biotech Inc. 342
Globeimmune, Inc. 343
NewLink Genetics Corporation 344
Tragara Pharmaceuticals, Inc. 345
Drais Pharmaceuticals, Inc. 346
Cellceutix Corporation 347
PharmaMar, S.A. 348
TVAX Biomedical, LLC 349
Quintessence Biosciences, Inc. 350
Sirnaomics, Inc. 351
Tigris Pharmaceuticals, Inc. 352
Genelux Corporation 353
Lipopharma 354
Biothera 355
Nereus Pharmaceuticals, Inc. 356
Viventia Biotechnologies Inc. 357
AVEO Pharmaceuticals, Inc. 358
Medisyn Technologies, Inc. 359
Kuhnil Pharmaceutical Co., Ltd. 360
Pierre Fabre Medicament 361
Pique Therapeutics 362
Clovis Oncology, Inc. 363
Cancer Therapeutics CRC Pty Ltd 364
Bioo Therapeutics 365
Jiangsu Kanion Pharmaceutical Co., Ltd. 366
Medical Enzymes AG 367
KAEL-GemVax 368
iCeutica, Inc. 369
Steba Laboratories Ltd. 370
Mebiopharm Co., Ltd. 371
Vichem Chemie Research Ltd. 372
Agennix AG 373
Regulon Inc. 374
Optimum Therapeutics, LLC 375
PharmaTech International, Inc. 376
Lung Cancer – Therapeutics Assessment 377
Assessment by Monotherapy Products 377
Assessment by Combination Products 378
Assessment by Route of Administration 379
Assessment by Molecule Type 381
Drug Profiles 384
eribulin mesylate - Drug Profile 384
Product Description 384
Mechanism of Action 384
R&D Progress 384
motesanib diphosphate - Drug Profile 386
Product Description 386
Mechanism of Action 386
R&D Progress 386
carboxyamidotriazole - Drug Profile 431
Product Description 431
Mechanism of Action 431
R&D Progress 431
belagenpumatucel-L - Drug Profile 432
Product Description 432
Mechanism of Action 432
R&D Progress 432
Cisplatin + Docetaxel - Drug Profile 492
Product Description 492
Mechanism of Action 492
R&D Progress 492
Sunitinib - Drug Profile 493
Product Description 493
Mechanism of Action 493
R&D Progress 493
Cisplatin + Docetaxel + Gemcitabine hydrochloride + Pemetrexed disodium + Vinorelbine ditartrate - Drug Profile 495
Product Description 495
Mechanism of Action 495
R&D Progress 495
pazopanib hydrochloride - Drug Profile 496
Product Description 496
Mechanism of Action 496
R&D Progress 496
Vinorelbine + Cisplatin - Drug Profile 497
Product Description 497
Mechanism of Action 497
R&D Progress 497
Talactoferrin + Carboplatin + Paclitaxel - Drug Profile 524
Product Description 524
Mechanism of Action 524
R&D Progress 524
Endostar + Vinorelbine + Cisplatin - Drug Profile 526
Product Description 526
Mechanism of Action 526
R&D Progress 526
KI-0501 - Drug Profile 528
Product Description 528
Mechanism of Action 528
R&D Progress 528
Iressa + Cisplatin + Pemetrexed - Drug Profile 529
Product Description 529
Mechanism of Action 529
R&D Progress 529
Lung Cancer Therapeutics – Drug Profile Updates 531
Lung Cancer Therapeutics – Discontinued Products 583
Lung Cancer Therapeutics - Dormant Products 600
Lung Cancer – Product Development Milestones 677
Featured News & Press Releases 677
Oct 19, 2012: Boehringer Ingelheim's Afatinib Demostrates Improvement In Lung Cancer Symptoms In Addition To Progression Free Survival In Phase III Study 677
Oct 17, 2012: Lilly Receives FDA Approval For New Use Of Alimta In Continuation Maintenance Setting For Advanced Nonsquamous Non-Small Cell Lung Cancer 678
Oct 12, 2012: Celgene's Abraxane Receives FDA Approval For First-Line Treatment Of Advanced Non-Small Cell Lung Cancer 679
Oct 09, 2012: Sunshine Biopharma Receives Scale-up Manufacturing Protocol For Adva-27a 680
Oct 03, 2012: NewLink Genetics Launches Adaptive Design Phase IIB/III Clinical Trial Of Tergenpumatucel-L Immunotherapy In Patients With Non-Small Cell Lung Cancer 680
Oct 02, 2012: ArQule And Daiichi Sankyo Announce Discontinuation Of Phase III MARQUEE Clinical Trial In Non-Small Cell Lung Cancer 682
Oct 02, 2012: Humanetics Receives Contract From National Cancer Institute To Study and Develop New Drug Candidate For Adjunctive Treatment Of Non-Small Cell Lung Cancer 682
Oct 02, 2012: Aduro Biotech Announces Enrollment Of First Patient In Mesothelioma Phase Ib Trial 683
Oct 02, 2012: Tesaro Announces Clearance Of Investigational New Drug Application For Anti-cancer Agent TSR-011 684
Oct 01, 2012: AVEO Announces Detailed Results Of Exploratory Phase II Study Evaluating Ficlatuzumab In First-Line Patients With Advanced Non-small Cell Lung Cancer 684
Appendix 686
Methodology 686
Coverage 686
Secondary Research 686
Primary Research 686
Expert Panel Validation 686
Contact Us 687
Disclaimer 687

List of Tables
Number of Products Under Development for Lung Cancer, H2 2012 29
Products under Development for Lung Cancer – Comparative Analysis, H2 2012 30
Number of Products under Development by Companies, H2 2012 32
Number of Products under Development by Companies, H2 2012 (Contd..1) 33
Number of Products under Development by Companies, H2 2012 (Contd..2) 34
Number of Products under Development by Companies, H2 2012 (Contd..3) 35
Number of Products under Development by Companies, H2 2012 (Contd..4) 36
Number of Products under Development by Companies, H2 2012 (Contd..5) 37
Number of Products under Development by Companies, H2 2012 (Contd..6) 38
Number of Products under Development by Companies, H2 2012 (Contd..7) 39
Number of Products under Development by Companies, H2 2012 (Contd..8) 40
Number of Products under Development by Companies, H2 2012 (Contd..9) 41
Number of Products under Development by Companies, H2 2012 (Contd..10) 42
Number of Products under Development by Companies, H2 2012 (Contd..11) 43
Number of Products under Development by Companies, H2 2012 (Contd..12) 44
Number of Products under Development by Companies, H2 2012 (Contd..13) 45
Number of Products under Development by Companies, H2 2012 (Contd..14) 46
Number of Products under Development by Companies, H2 2012 (Contd..15) 47
Number of Products under Development by Companies, H2 2012 (Contd..16) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 59
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 60
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 61
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 62
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 63
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 64
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 65
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 66
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 67
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 68
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 69
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 70
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 71
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 72
Comparative Analysis by Late Stage Development, H2 2012 73
Comparative Analysis by Mid Clinical Stage Development, H2 2012 74
Comparative Analysis by Early Clinical Stage Development, H2 2012 75
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 76
Products under Development by Companies, H2 2012 77
Products under Development by Companies, H2 2012 (Contd..1) 78
Products under Development by Companies, H2 2012 (Contd..2) 79
Products under Development by Companies, H2 2012 (Contd..3) 80
Products under Development by Companies, H2 2012 (Contd..4) 81
Products under Development by Companies, H2 2012 (Contd..5) 82
Products under Development by Companies, H2 2012 (Contd..6) 83
Products under Development by Companies, H2 2012 (Contd..7) 84
Products under Development by Companies, H2 2012 (Contd..8) 85
Products under Development by Companies, H2 2012 (Contd..9) 86
Products under Development by Companies, H2 2012 (Contd..10) 87
Products under Development by Companies, H2 2012 (Contd..11) 88
Products under Development by Companies, H2 2012 (Contd..12) 89
Products under Development by Companies, H2 2012 (Contd..13) 90
Products under Development by Companies, H2 2012 (Contd..14) 91
Products under Development by Companies, H2 2012 (Contd..15) 92
Products under Development by Companies, H2 2012 (Contd..16) 93
Products under Development by Companies, H2 2012 (Contd..17) 94
Products under Development by Companies, H2 2012 (Contd..18) 95
Products under Development by Companies, H2 2012 (Contd..19) 96
Products under Development by Companies, H2 2012 (Contd..20) 97
Products under Development by Companies, H2 2012 (Contd..21) 98
Products under Development by Companies, H2 2012 (Contd..22) 99
Products under Development by Companies, H2 2012 (Contd..23) 100
Products under Development by Companies, H2 2012 (Contd..24) 101
Products under Development by Companies, H2 2012 (Contd..25) 102
Products under Development by Companies, H2 2012 (Contd..26) 103
Products under Development by Companies, H2 2012 (Contd..27) 104
Products under Development by Companies, H2 2012 (Contd..28) 105
Products under Development by Companies, H2 2012 (Contd..29) 106
Products under Development by Companies, H2 2012 (Contd..30) 107
Products under Development by Companies, H2 2012 (Contd..31) 108
Products under Investigation by Universities/Institutes, H2 2012 109
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 110
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 111
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 112
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 113
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 114
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 115
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 116
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 117
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 118
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 119
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 120
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 121
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 122
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 123
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 124
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 125
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 126
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 127
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 128
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 129
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 130
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 131
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 132
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 133
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 134
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 135
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 136
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 137
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 138
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 139
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 140
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 141
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 142
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 143
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 144
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 145
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 146
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 147
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 148
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 149
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 150
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 151
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 152
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 153
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 154
Products under Investigation by Universities/Institutes, H2 2012 (Contd..46) 155
Products under Investigation by Universities/Institutes, H2 2012 (Contd..47) 156
Products under Investigation by Universities/Institutes, H2 2012 (Contd..48) 157
Products under Investigation by Universities/Institutes, H2 2012 (Contd..49) 158
Products under Investigation by Universities/Institutes, H2 2012 (Contd..50) 159
Products under Investigation by Universities/Institutes, H2 2012 (Contd..51) 160
Products under Investigation by Universities/Institutes, H2 2012 (Contd..52) 161
Products under Investigation by Universities/Institutes, H2 2012 (Contd..53) 162
Products under Investigation by Universities/Institutes, H2 2012 (Contd..54) 163
Products under Investigation by Universities/Institutes, H2 2012 (Contd..55) 164
Products under Investigation by Universities/Institutes, H2 2012 (Contd..56) 165
Products under Investigation by Universities/Institutes, H2 2012 (Contd..57) 166
Products under Investigation by Universities/Institutes, H2 2012 (Contd..58) 167
Products under Investigation by Universities/Institutes, H2 2012 (Contd..59) 168
Products under Investigation by Universities/Institutes, H2 2012 (Contd..60) 169
Products under Investigation by Universities/Institutes, H2 2012 (Contd..61) 170
Products under Investigation by Universities/Institutes, H2 2012 (Contd..62) 171
Products under Investigation by Universities/Institutes, H2 2012 (Contd..63) 172
Products under Investigation by Universities/Institutes, H2 2012 (Contd..64) 173
Products under Investigation by Universities/Institutes, H2 2012 (Contd..65) 174
Products under Investigation by Universities/Institutes, H2 2012 (Contd..66) 175
Bristol-Myers Squibb Company, H2 2012 176
Johnson & Johnson, H2 2012 177
Boehringer Ingelheim GmbH, H2 2012 178
F. Hoffmann-La Roche Ltd., H2 2012 179
Kyowa Hakko Kirin Co., Ltd., H2 2012 180
Celsion Corporation, H2 2012 181
Abbott Laboratories, H2 2012 182
Biogen Idec Inc., H2 2012 183
Helix BioPharma Corp., H2 2012 184
Amgen Inc., H2 2012 185
Sanofi-Aventis, H2 2012 186
AstraZeneca PLC, H2 2012 187
Eli Lilly and Company, H2 2012 188
Viralytics Ltd., H2 2012 190
GlaxoSmithKline plc, H2 2012 191
Genentech, Inc., H2 2012 192
Antigenics, Inc., H2 2012 193
Bavarian Nordic A/S, H2 2012 194
MedImmune LLC, H2 2012 195
Isis Pharmaceuticals, Inc., H2 2012 196
Daiichi Sankyo Company, Ltd, H2 2012 197
Merck & Co., Inc., H2 2012 198
AbGenomics International, Inc., H2 2012 199
FASgen, Inc., H2 2012 200
A&G Pharmaceutical, Inc., H2 2012 201
Infinity Pharmaceuticals, Inc., H2 2012 202
Takeda Pharmaceutical Company Limited, H2 2012 203
YM BioSciences Inc., H2 2012 204
Light Sciences Oncology, Inc., H2 2012 205

List of Figures
Number of Products under Development for Lung Cancer, H2 2012 29
Products under Development for Lung Cancer – Comparative Analysis, H2 2012 30
Products under Development by Companies, H2 2012 31
Products under Investigation by Universities/Institutes, H2 2012 49
Late Stage Products, H2 2012 73
Mid Clinical Stage Products, H2 2012 74
Early Clinical Stage Products, H2 2012 75
Discovery and Pre-Clinical Stage Products, H2 2012 76
Assessment by Monotherapy Products, H2 2012 377
Assessment by Combination Products, H2 2012 378
Assessment by Route of Administration, H2 2012 379
Assessment by Stage and Route of Administration, H2 2012 380
Assessment by Molecule Type, H2 2012 381
Assessment by Stage and Molecule Type, H2 2012 382

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos